BiotechTubeBiotechTube
Home/Enanta Pharmaceuticals/Tara L. Kieffer, Ph.D.
TL

Tara L. Kieffer, Ph.D.

Chief Product Strategy Officer

Enanta Pharmaceuticals

Therapeutic Areas

VirologyImmunology

Enanta Pharmaceuticals Pipeline

DrugIndicationPhase
Zelicapavir (EDP-938)Respiratory Syncytial Virus (RSV) InfectionPhase 2
EDP-323Respiratory Syncytial Virus (RSV) InfectionPhase 2a
EDP-235COVID-19 (SARS-CoV-2 Infection)Phase 2
EDP-978Type 2 Immune Diseases (e.g., Chronic Spontaneous Urticaria)Pre-clinical
STAT6 Inhibitor ProgramType 2 Inflammatory DiseasesPre-clinical
MRGPRX2 Inhibitor ProgramType 2 Inflammatory DiseasesPre-clinical

Leadership Team at Enanta Pharmaceuticals

JR
Jay R. Luly, Ph.D.
President, Chief Executive Officer and Director
MP
Matthew P. Kowalsky, J.D.
Chief Legal Officer
View full Enanta Pharmaceuticals profile